Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Derived from a partial sequence of the naturally occurring Body Protection Compound (BPC) , this peptide is commonly used in controlled invitro and preclinical research environments
Lower starting doses also help distinguish peptide effects from coincidental events
End-stage renal disease or severe hepatic impairment requires caution
Daily use may be too strong for beginners
Let's clear up a few of the most commonand potentially dangerousmisunderstandings about BPC-157 so you can make an informed decision about your recovery